Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression quotes treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the Treatment-Resistant Depression Market Research Report
The FDA approved SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
In March 2019, the FDA approved Spravato-non-competitive N-methyl D-aspartate (NMDA) receptor antagonist, in conjunction with an oral antidepressant, for the TRD treatment in adults. It is the first-ever approved NMDA therapy for TRD.
Dominant players such as Eli Lilly and Company, Johnson& Johnson, Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals, and others involved in developing targeted TRD therapeutics.
The Treatment-Resistant Depression market is expected to show positive growth, mainly attributed to an increased number of TRD cases and the expected launch of therapies such as AXS-05, ALKS-5461, Cariprazine, Seltorexant, Pimavanserin, MIJ821, Esketamine DPI, Psilocybin, REL-1017, and others.
With a novel mechanism of action, these therapies may change the Treatment-Resistant Depression treatment regimen by 2030.
For further information on Market Impact by Therapies, visit: Treatment-Resistant Depression (TRD) Market Trends
Treatment-Resistant Depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder and causes a continuous feeling of sadness and loss of interest that can interfere with day-to-day life.
According to DelveInsight's analysts, the total diagnosed Treatment-Resistant Depression prevalent population in 7MM was estimated to be 4,464,781 cases in 2017. The females appear to have a predisposition to Treatment-Resistant Depression, which is why a higher percentage of prevalence was observed in females than males in the United States.
The TRD Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Total diagnosed prevalent cases
Gender-specific cases
Age-specific cases
Get a sample copy of this report: Treatment-Resistant Depression Market Landscape
Treatment-Resistant Depression Treatment Market
The TRD therapeutic market size is mainly regarded by the management options involving pharmacologic treatment options and non-pharmacological therapies.
Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment.
Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.
The combination strategy is only recommended in partial response cases after 4 to 6 weeks of adequate treatment. In the first-line, the recommended strategies comprise combinations such as SSRI + α2 antagonist, SNRI + α2 antagonist, and Tricyclic antidepressant + α2-antagonist. In the second-line treatment, an association between SSRIs, SNRIs, or tricyclic antidepressants and agomelatine can be proposed.
Non-pharmacological therapies involve electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy comprise majorly cognitive-behavioural therapy (CBT) and interpersonal therapy (IPT).
Despite an increasing variety of choices for the treatment of TRD, this condition continues to be universally undefined and represents an area of unmet medical need. There are only a few known approved TRD pharmacological agents. So, various biotechnological companies are working towards the development of targeted TRD therapeutics.
